This is a preview of subscription content, log in via an institution to check access.
Access this article
We’re sorry, something doesn't seem to be working properly.
Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.
Reference
Barbaro D, et al. Low-intermediate dose of lenvatinib in anaplastic thyroid cancer is highly effective and safe. BMJ Case Reports 13: No. 12, 22 Dec 2020. Available from: URL: http://doi.org/10.1136/bcr-2020-236934
Rights and permissions
About this article
Cite this article
Ciclosporin/everolimus. Reactions Weekly 1843, 103 (2021). https://doi.org/10.1007/s40278-021-91205-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-021-91205-5